Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 18/20 | 0.59 |
| ▸ | ERBB2 | P04626 | 15/20 | 0.59 |
| ▸ | GAK | O14976 | 1/20 | 0.57 |
| ▸ | ERBB4 | Q15303 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31041173 | 0.91 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL29229152 | 0.91 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL27852353 | 0.90 | EGFR (0.54) | EGFRERBB2GAKERBB4 | |
| SCHEMBL29693649 | 0.89 | EGFR (0.73) | EGFRERBB2GAKERBB4 | |
| SCHEMBL14595000 | 0.89 | EGFR (0.58) | EGFRERBB2GAKERBB4 | |
| SCHEMBL141514 | 0.89 | EGFR (0.73) | EGFRERBB2GAKERBB4 | |
| SCHEMBL13966848 | 0.89 | EGFR (0.60) | EGFRERBB2GAKERBB4 | |
| SCHEMBL9910666 | 0.88 | EGFR (0.66) | EGFRERBB2GAK | |
| Hydrochloric Acid SCHEMBL215037 | 0.88 | EGFR (0.72) | EGFRERBB2GAKERBB4 | |
| Hydrochloric Acid SCHEMBL8809228 | 0.87 | EGFR (0.59) | EGFRERBB2GAK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICALS USA, INC. | 2010-08-05 | — | — | US | claimed |
| WO-2010017387-A2 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-11 | — | — | WO | claimed |
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICALS USA, INC. | 2010-08-05 | — | — | US | disclosed |
| WO-2010017387-A2 | LAPATINIB INTERMEDIATES | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2010-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197915-A1 | LAPATINIB INTERMEDIATES | ERBB2, ABL1, EGFR | EGFR 3/4885ERBB2 1/4885GAK 327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.